A Parallel Group, Double-Blind, Randomized, Placebo Controlled, Dose-Ranging Phase 2 Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of ALD403 Administered Intravenously in Patients With Chronic Migraine

Trial Profile

A Parallel Group, Double-Blind, Randomized, Placebo Controlled, Dose-Ranging Phase 2 Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of ALD403 Administered Intravenously in Patients With Chronic Migraine

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Sep 2017

At a glance

  • Drugs Eptinezumab (Primary)
  • Indications Migraine
  • Focus Therapeutic Use
  • Sponsors Alder Biopharmaceuticals
  • Most Recent Events

    • 10 Sep 2017 Results of this trial and 2 other trials (refer CTP: 228412, 259778) were presented at the 2017 International Headache Society
    • 10 Sep 2017 Results of post hoc analysis to examine the change in triptan use among patients with CM 12 weeks following administration of ALD403, presented at the 2017 International Headache Society.
    • 10 Sep 2017 Results of post hoc analysis assessing the migraine episodes and migraine hours experienced 24 hours after a single IV infusion of ALD403 (300 mg or 100 mg) or placebo were compared to baseline, were presented at the 2017 International Headache Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top